Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+/HER2-advanced breast cancer
Purpose: This study aims to evaluate the cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib-fulvestrant for treating advanced HR+/HER2-breast cancer patients with PIK3CA mutations from both United States (U.S.) and Chinese healthcare system perspectives. Methods: A part...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Elsevier
2026-02-01
|
| Serie: | Breast |
| Soggetti: | |
| Accesso online: | http://www.sciencedirect.com/science/article/pii/S0960977626000032 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|